214 related articles for article (PubMed ID: 31287387)
1. Contrast-enhanced US with Perfluorobutane for Hepatocellular Carcinoma Surveillance: A Multicenter Diagnostic Trial (SCAN).
Park JH; Park MS; Lee SJ; Jeong WK; Lee JY; Park MJ; Lee SS; Han K; Nam CM; Park SH; Lee KH
Radiology; 2019 Sep; 292(3):638-646. PubMed ID: 31287387
[TBL] [Abstract][Full Text] [Related]
2. Contrast-enhanced US with Perfluorobutane(Sonazoid) used as a surveillance test for Hepatocellular Carcinoma (HCC) in Cirrhosis (SCAN): an exploratory cross-sectional study for a diagnostic trial.
Park JH; Park MS; Lee SJ; Jeong WK; Lee JY; Park MJ; Han K; Nam CM; Park SH; Lee KH
BMC Cancer; 2017 Apr; 17(1):279. PubMed ID: 28420329
[TBL] [Abstract][Full Text] [Related]
3. Contrast-enhanced US with Sulfur Hexafluoride and Perfluorobutane for the Diagnosis of Hepatocellular Carcinoma in Individuals with High Risk.
Kang HJ; Lee JM; Yoon JH; Lee K; Kim H; Han JK
Radiology; 2020 Oct; 297(1):108-116. PubMed ID: 32749211
[TBL] [Abstract][Full Text] [Related]
4. Validation of US Liver Imaging Reporting and Data System Version 2017 in Patients at High Risk for Hepatocellular Carcinoma.
Son JH; Choi SH; Kim SY; Jang HY; Byun JH; Won HJ; Lee SJ; Lim YS
Radiology; 2019 Aug; 292(2):390-397. PubMed ID: 31210614
[TBL] [Abstract][Full Text] [Related]
5. Comparison of biannual ultrasonography and annual non-contrast liver magnetic resonance imaging as surveillance tools for hepatocellular carcinoma in patients with liver cirrhosis (MAGNUS-HCC): a study protocol.
Kim HA; Kim KA; Choi JI; Lee JM; Lee CH; Kang TW; Ku YM; Lee SL; Park YS; Yoon JH; Kim SH; Choi MH
BMC Cancer; 2017 Dec; 17(1):877. PubMed ID: 29268722
[TBL] [Abstract][Full Text] [Related]
6. Irregular Defects in Hepatocellular Carcinomas During the Kupffer Phase of Contrast-Enhanced Ultrasonography with Perfluorobutane Microbubbles: Pathological Features and Metastatic Recurrence After Surgical Resection.
Nuta J; Shingaki N; Ida Y; Shimizu R; Hayami S; Ueno M; Fukatsu K; Itonaga M; Yoshida T; Maeda Y; Moribata K; Deguchi H; Maekita T; Iguchi M; Kato J; Yamaue H; Tamai H
Ultrasound Med Biol; 2017 Sep; 43(9):1829-1836. PubMed ID: 28625558
[TBL] [Abstract][Full Text] [Related]
7. MRI With Liver-Specific Contrast for Surveillance of Patients With Cirrhosis at High Risk of Hepatocellular Carcinoma.
Kim SY; An J; Lim YS; Han S; Lee JY; Byun JH; Won HJ; Lee SJ; Lee HC; Lee YS
JAMA Oncol; 2017 Apr; 3(4):456-463. PubMed ID: 27657493
[TBL] [Abstract][Full Text] [Related]
8. Perfluorobutane-enhanced ultrasonography with a Kupffer phase: improved diagnostic sensitivity for hepatocellular carcinoma.
Hwang JA; Jeong WK; Kang HJ; Lee ES; Park HJ; Lee JM
Eur Radiol; 2022 Dec; 32(12):8507-8517. PubMed ID: 35705829
[TBL] [Abstract][Full Text] [Related]
9. Value of post-vascular phase (Kupffer imaging) by contrast-enhanced ultrasonography using Sonazoid in the detection of hepatocellular carcinoma.
Goto E; Masuzaki R; Tateishi R; Kondo Y; Imamura J; Goto T; Ikeda H; Akahane M; Shiina S; Omata M; Yoshida H; Koike K
J Gastroenterol; 2012 Apr; 47(4):477-85. PubMed ID: 22200940
[TBL] [Abstract][Full Text] [Related]
10. LI-RADS Version 2017 versus Version 2018: Diagnosis of Hepatocellular Carcinoma on Gadoxetate Disodium-enhanced MRI.
Lee SM; Lee JM; Ahn SJ; Kang HJ; Yang HK; Yoon JH
Radiology; 2019 Sep; 292(3):655-663. PubMed ID: 31310175
[TBL] [Abstract][Full Text] [Related]
11. B-Mode Ultrasonography versus Contrast-Enhanced Ultrasonography for Surveillance of Hepatocellular Carcinoma: A Prospective Multicenter Randomized Controlled Trial.
Kudo M; Ueshima K; Osaki Y; Hirooka M; Imai Y; Aso K; Numata K; Kitano M; Kumada T; Izumi N; Sumino Y; Ogawa C; Akazawa K
Liver Cancer; 2019 Jul; 8(4):271-280. PubMed ID: 31602370
[TBL] [Abstract][Full Text] [Related]
12. Noncontrast magnetic resonance imaging versus ultrasonography for hepatocellular carcinoma surveillance (MIRACLE-HCC): study protocol for a prospective randomized trial.
An C; Kim DY; Choi JY; Han KH; Roh YH; Kim MJ
BMC Cancer; 2018 Sep; 18(1):915. PubMed ID: 30249190
[TBL] [Abstract][Full Text] [Related]
13. Contribution of Contrast-Enhanced Sonography With Perfluorobutane Microbubbles for Diagnosis of Recurrent Hepatocellular Carcinoma.
Shagdarsuren B; Tamai H; Shingaki N; Mori Y; Maeshima S; Nuta J; Maeda Y; Moribata K; Niwa T; Deguchi H; Inoue I; Maekita T; Iguchi M; Kato J; Ichinose M
J Ultrasound Med; 2016 Jul; 35(7):1383-91. PubMed ID: 27208196
[TBL] [Abstract][Full Text] [Related]
14. Role of contrast-enhanced ultrasound with Perfluorobutane in lesion detection, guidance for microwave ablation, and response assessment of hepatocellular carcinoma.
Mukund A; Bansal A; Patidar Y; Thapar S; Sharma MK; Sarin SK
Abdom Radiol (NY); 2022 Oct; 47(10):3459-3467. PubMed ID: 35842563
[TBL] [Abstract][Full Text] [Related]
15. Assessment of hepatocellular carcinoma by contrast-enhanced ultrasound with perfluorobutane microbubbles: comparison with dynamic CT.
Mandai M; Koda M; Matono T; Nagahara T; Sugihara T; Ueki M; Ohyama K; Murawaki Y
Br J Radiol; 2011 Jun; 84(1002):499-507. PubMed ID: 20959373
[TBL] [Abstract][Full Text] [Related]
16. Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1,006 nodules.
Terzi E; Iavarone M; Pompili M; Veronese L; Cabibbo G; Fraquelli M; Riccardi L; De Bonis L; Sangiovanni A; Leoni S; Zocco MA; Rossi S; Alessi N; Wilson SR; Piscaglia F;
J Hepatol; 2018 Mar; 68(3):485-492. PubMed ID: 29133247
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Contrast-enhanced US LI-RADS version 2017: Application on 2020 Liver Nodules in Patients with Hepatitis B Infection.
Zheng W; Li Q; Zou XB; Wang JW; Han F; Li F; Huang LS; Li AH; Zhou JH
Radiology; 2020 Feb; 294(2):299-307. PubMed ID: 31769742
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of US Surveillance of Hepatocellular Carcinoma in Chronic Hepatitis B: US LI-RADS Visualization Score.
Park MK; Lee DH; Hur BY; Lee HC; Lee YB; Yu SJ; Kim YJ; Yoon JH; Lee JH
Radiology; 2023 Jun; 307(5):e222106. PubMed ID: 37249427
[TBL] [Abstract][Full Text] [Related]
19. Gadoxetate-enhanced Abbreviated MRI for Hepatocellular Carcinoma Surveillance: Preliminary Experience.
Brunsing RL; Chen DH; Schlein A; Wolfson T; Gamst A; Mamidipalli A; Vietti Violi N; Marks RM; Taouli B; Loomba R; Kono Y; Sirlin CB
Radiol Imaging Cancer; 2019 Nov; 1(2):e190010. PubMed ID: 33778680
[TBL] [Abstract][Full Text] [Related]
20. Utility of Contrast-enhanced Ultrasonography with Perflubutane for Determining Histologic Grade in Hepatocellular Carcinoma.
Tada T; Kumada T; Toyoda H; Ito T; Sone Y; Kaneoka Y; Maeda A; Okuda S; Otobe K; Takahashi K
Ultrasound Med Biol; 2015 Dec; 41(12):3070-8. PubMed ID: 26360976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
